A Phase 1 Study of SP-02L (Darinaparsin for Injection) in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea

Trial Profile

A Phase 1 Study of SP-02L (Darinaparsin for Injection) in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Darinaparsin (Primary)
  • Indications Anaplastic large cell lymphoma; Peripheral T-cell lymphoma; T cell lymphoma
  • Focus Adverse reactions
  • Sponsors Solasia Pharma
  • Most Recent Events

    • 08 Dec 2015 Pooled results (n=23) of this and other trial (see profile 206743) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 03 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 01 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top